Ambrosia Raises $100M to Develop Small Molecule GLP-1 Drugs

Got story updates? Submit your updates here. ›

Ambrosia Biosciences, a Colorado-based biotech company, has raised $100 million in a Series B funding round to advance its pipeline of small molecule GLP-1 agonists for obesity and cardiometabolic disorders. The oversubscribed round was co-led by Blue Owl Healthcare Opportunities, Redmile, and Deep Track Capital, with participation from other investors. Ambrosia plans to use the funds to initiate a Phase 1 study of its lead asset and further develop its broader small molecule portfolio, which also includes candidates targeting GIP and amylin pathways.

Why it matters

While peptide-based GLP-1 agonists like Novo Nordisk's Ozempic and Eli Lilly's Mounjaro have dominated the market, Ambrosia's small molecule approach could offer advantages in terms of oral bioavailability, metabolic stability, and manufacturing. If successful, Ambrosia's pipeline could provide new treatment options for obesity and related cardiometabolic conditions.

The details

Ambrosia's small molecule GLP-1 agonists are designed to provide an oral alternative to the currently available injectable peptide-based therapies. Compared to peptides, small molecules generally have better metabolic stability and can be more easily manufactured. The company's lead asset will now advance to a Phase 1 clinical trial, while the broader pipeline targeting GIP and amylin pathways will also be further developed with the new funding.

• Ambrosia completed the $100 million Series B funding round in April 2026.
• The company plans to initiate a Phase 1 study of its lead small molecule GLP-1 agonist in the coming months.

What’s next

Ambrosia plans to initiate a Phase 1 clinical trial of its lead small molecule GLP-1 agonist in the coming months, following the completion of its $100 million Series B funding round.